AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sensorion Announces an Oral Presentation at the 5th Congress of European ORL-Head & Neck Surgery in Brussels

July 1, 2019

MONTPELLIER, France--(BUSINESS WIRE)--Jul 1, 2019--

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, has participated in a roundtable session about “Novel hearing therapeutics; what does it mean for the ENT surgeon” at the 5th Congress of European ORL-Head & Neck Surgery, held in Brussels, the 30 th of June, 2019.

Prior to the roundtable discussion with internationally renowned clinicians, Sensorion’s presentations main topic covered “ Drug therapy development for inner ear diseases, - common challenges and potential of circulating biomarkers”. The talk addressed some common challenges in translational development for inner ear diseases in terms of lacking etiologies, paucity of validated pharmacodynamic endpoints and how circulating biomarkers in the future may not only facilitate clinical drug development but also open the door to personalized medicine in the ENT domain.

A propos de Sensorion

Sensorion is a pioneering clinical-stage biopharmaceutical company, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, vertigo and tinnitus. Our clinical-stage portfolio includes two phase 2 products: Seliforant (SENS-111) under investigation for acute unilateral vestibulopathy and Arazasetron (SENS-401) for sudden sensorineural hearing loss (SSNHL). We have built a unique R&D technology platform to expand our understanding of the physiopathology and etiology of inner ear related diseases enabling us to select the best targets and modalities for drug candidates. We also identify biomarkers to improve diagnosis and treatment of these underserved illnesses. Sensorion is launching in the second half of 2019 two preclinical gene programs aiming to correct hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. We are uniquely placed through our platforms and pipeline of potential therapeutics to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders; a significant global unmet need in medicine today.

www.sensorion-pharma.com

Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN

Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the ‘Document de référence’ registration document filed with the ‘Autorité des Marchés Financiers’ (AMF French Financial Market Authority) on September 7th, 2017 under n°R.17-062 and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190630005024/en/

CONTACT: Sensorion

Nawal Ouzren

CEO

contact@sensorion-pharma.com

Tel: +33 467 207 730

Catherine Leveau

Finance & Financial communication

catherine.leveau@sensorion-pharma.com

Tel: +33 467 207 730

KEYWORD: EUROPE BELGIUM FRANCE

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL ONCOLOGY SURGERY HEALTH CLINICAL TRIALS

SOURCE: Sensorion

Copyright Business Wire 2019.

PUB: 07/01/2019 01:30 AM/DISC: 07/01/2019 01:30 AM

http://www.businesswire.com/news/home/20190630005024/en

All contents © copyright 2019 The Associated Press. All rights reserved.